News

Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis, Moves Toward FDA Accelerated Approval
Neuronata-R®, an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), ...
CorestemChemon Inc.: Neuronata-R Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis, Moves Toward FDA Accelerated Approval
Meaningful efficacy observed in slow-progressor subgroup; NfL biomarker improvements support potential for accelerated regulatory pathway SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- ...
Bladder cancer treatment reprograms bone marrow to boost immune system's cancer-fighting ability
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first ...
News-Medical.Net on MSN6h
BCG immunotherapy reprograms bone marrow to boost cancer defense
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first ...
Scientists find promise in a new peptide drug to combat a deadly brain cancer
A lab-designed molecule developed and extensively studied by scientists with Virginia Tech's Fralin Biomedical Research ...